首頁 > 市場調查報告書 > 製藥

疼痛

氫可酮市場規模、佔有率和成長分析（按劑型、分銷通路、應用、最終用戶和地區分類）－2026-2033年產業預測

市場調查報告書

商品編碼

1900203

氫可酮市場規模、佔有率和成長分析（按劑型、分銷通路、應用、最終用戶和地區分類）－2026-2033年產業預測

Morphine Market Size, Share, and Growth Analysis, By Form (Oral Tablets, Injection), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies), By Application, By End User, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月23日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計到 2024 年，全球氫可酮市場規模將達到 323.4 億美元，到 2025 年將達到 348.3 億美元，到 2033 年將達到 630.5 億美元，預測期（2026-2033 年）的複合年成長率為 7.7%。

全球氫可酮市場是製藥業的重要組成部分，致力於生產和銷售強效鎮痛藥，為患有各種疾病的患者提供有效的疼痛管理。氫可酮在醫院、診所和安寧療護機構中發揮著至關重要的作用，能夠緩解劇烈疼痛，尤其適用於癌症和術後復健等慢性疼痛患者。疼痛相關疾病盛行率的上升以及人們對醫療保健系統中有效疼痛管理需求的日益重視，推動了該市場的發展。然而，也存在一些挑戰，包括潛在的濫用風險和監管限制。儘管面臨這些挑戰，疼痛管理技術的進步和安寧療護服務的擴展預計將為市場擴張帶來巨大的成長機遇，最終有助於提高患者的舒適度和生活品質。

全球氫可酮市場促進因素

慢性疼痛疾病（包括癌症、神經病變和神經性疼痛）的增加是氫可酮市場的主要促進因素。癌症病例和其他慢性疾病的預期成長推動了對有效止痛藥（尤其是氫可酮）的需求，以緩解劇烈疼痛。隨著醫療系統和患者尋求更有效的疼痛管理方案，氫可酮等強效鴉片類藥物的使用量正在上升。這一趨勢凸顯了氫可酮在治療慢性疼痛方面的重要作用，並最終推動了這種重要藥物的全球市場成長。

限制全球氫可酮市場的因素

全球氫可酮市場受到針對鴉片類藥物的嚴格監管環境的限制。為了應對濫用、成癮和過量用藥的擔憂，世界各國政府和衛生部門都實施了嚴格的監管措施。這些措施包括處方限制、監測系統和安全用藥指南，旨在解決鴉片類藥物危機。儘管這些法規的初衷良好，但它們給生產商和醫療服務提供者帶來了巨大的挑戰，阻礙了合規性，同時也限制了真正有醫療需求的患者獲得氫可酮的途徑。這種複雜的環境使得在患者照護和監管限制之間尋求平衡變得尤為重要，從而影響了市場動態。

全球氫可酮市場趨勢

全球氫可酮市場的一個顯著趨勢是日益重視個人化疼痛管理策略。醫療服務提供者和研究人員越來越關注量身定做的治療方案，這些方案充分考慮了患者的個別特徵、遺傳因素和特定的疼痛情況。這種向個人化醫療的轉變有助於最佳化包括氫可酮在內的鴉片類藥物治療，因為它能夠識別出副作用和療效不佳的高風險患者。因此，這一趨勢不僅代表疼痛管理實踐的進步，而且有望增加特定患者群體對氫可酮的需求，因為他們需要更有效、更安全的鎮痛方法。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2025 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2023-2025年營收年比比較

主要企業簡介

Pfizer Inc.（USA）
Teva Pharmaceutical Industries Ltd.（Israel）
Hikma Pharmaceuticals PLC（UK）
Mallinckrodt Pharmaceuticals（Ireland）
Boehringer Ingelheim GmbH（Germany）
Gerot Lannach（Austria）
Dongbei Pharmaceutical Group Co.（China）
Taiji Group Southwest Pharmaceutical Co.（China）
Sun Pharmaceutical Industries Ltd.（India）
Sanofi SA（France）
Johnson & Johnson（USA）
Novartis International AG（Switzerland）
GlaxoSmithKline plc（UK）
AstraZeneca plc（UK）
Eli Lilly and Company（USA）
Bayer AG（Germany）
Roche Holding AG（Switzerland）
Merck & Co., Inc.（USA）

結論與建議

簡介目錄

Product Code: SQMIG35H2204

Global Morphine Market size was valued at USD 32.34 Billion in 2024 and is poised to grow from USD 34.83 Billion in 2025 to USD 63.05 Billion by 2033, growing at a CAGR of 7.7% during the forecast period (2026-2033).

The global morphine market represents a critical sector of the pharmaceutical industry dedicated to the production and distribution of this potent analgesic, essential for effective pain management in patients with various medical conditions. Morphine plays a key role in alleviating severe pain experienced in hospitals, clinics, and palliative care settings, particularly for individuals facing chronic pain issues such as cancer and postoperative recovery. The market is driven by the rising prevalence of pain-related disorders and the increasing understanding of the need for efficient pain management within healthcare frameworks. However, it faces challenges such as potential misuse and regulatory constraints. Despite these issues, advancements in pain management technologies and growth in palliative care services present significant opportunities for market expansion, ultimately enhancing patient comfort and quality of life.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Morphine market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Morphine Market Segments Analysis

Global Morphine Market is segmented by Form, Distribution Channel, Application, End User and region. Based on Form, the market is segmented into Oral Tablets, Injection, Capsule and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others. Based on Application, the market is segmented into Pain Management, Diarrhea Suppressant, Cold & Cough Suppressant and Others. Based on End User, the market is segmented into Hospitals & Clinics, Ambulatory Surgical Centers and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Morphine Market

The increasing prevalence of chronic pain conditions, including cancer, musculoskeletal disorders, and neuropathic pain, serves as a significant catalyst for the morphine market. The expected rise in cancer cases and other chronic ailments has heightened the demand for effective analgesics, notably morphine, to alleviate severe pain. As healthcare systems and patients seek more robust pain management solutions, the utilization of potent opioids like morphine is on the rise. This trend underscores the crucial role morphine plays in addressing chronic pain, ultimately propelling the growth of the global market for this essential medication.

Restraints in the Global Morphine Market

The global morphine market is hindered by a stringent regulatory landscape focusing on opioid medications. In response to concerns over misuse, addiction, and overdose, various governments and healthcare authorities have implemented strict regulations. These measures encompass prescription limitations, monitoring systems, and guidelines tailored for safe administration, all designed to combat the opioid crisis. While well-intentioned, these regulations present significant challenges for manufacturers and healthcare providers, affecting their ability to ensure compliance while simultaneously limiting access to morphine for patients with legitimate medical needs. This complex environment creates a balancing act between patient care and regulatory constraints, impacting the overall market dynamics.

Market Trends of the Global Morphine Market

A significant trend in the global morphine market is the growing emphasis on personalized pain management strategies. Healthcare providers and researchers are increasingly focusing on tailored treatment approaches that take into account individual patient characteristics, genetic factors, and specific pain profiles. This shift towards personalized care enhances the optimization of opioid therapies, including morphine, by identifying patients who may be at higher risk for adverse reactions or ineffectiveness. As such, this trend not only signifies an evolution in pain management practices but also promises to elevate the demand for morphine in targeted patient populations seeking more effective and safer pain relief options.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Case Studies

Global Morphine Market Size by Form & CAGR (2026-2033)

Market Overview
Oral Tablets
Injection
Capsule
Others

Global Morphine Market Size by Distribution Channel & CAGR (2026-2033)

Market Overview
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Global Morphine Market Size by Application & CAGR (2026-2033)

Market Overview
Pain Management
Diarrhea Suppressant
Cold & Cough Suppressant
Others

Global Morphine Market Size by End User & CAGR (2026-2033)

Market Overview
Hospitals & Clinics
Ambulatory Surgical Centers
Others

Global Morphine Market Size & CAGR (2026-2033)

North America (Form, Distribution Channel, Application, End User)
- US
- Canada
Europe (Form, Distribution Channel, Application, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Form, Distribution Channel, Application, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Form, Distribution Channel, Application, End User)
- Brazil
- Rest of Latin America
Middle East & Africa (Form, Distribution Channel, Application, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Pfizer Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hikma Pharmaceuticals PLC (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mallinckrodt Pharmaceuticals (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gerot Lannach (Austria)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Dongbei Pharmaceutical Group Co. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Taiji Group Southwest Pharmaceutical Co. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sun Pharmaceutical Industries Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis International AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche Holding AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments